Olivier Quintin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Olivier Quintin has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Jessica Kasza
School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia
2 shared publications - Nathan Davies
Patient and Public Involvement Partner, UK
2 shared publications - Sarah Markham
Department of Biostatistics & Health Informatics, King’s College London, London, United Kingdom
2 shared publications - Antoine Bénard
Clinical Epidemiology Unit (USMR), Pôle de Santé Publique, Centre Hospitalier Universitaire de Bordeaux, F-33076 Bordeaux, France
1 shared publication - Christian Combe
INSERM, Bordeaux Public Health, University of Bordeaux , Bordeaux
1 shared publication - Claire Rigothier
Laboratoire de Bioingénierie Tissulaire, Institut National de la Santé et de la Recherche Médicale, University of Bordeaux, U1026, F-33000 Bordeaux, France
1 shared publication
Latest Publications
- Open Access
- 27 June 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 198, 112395
Small numbers of clusters in cluster randomised trials: a scoping review of problems and proposed solutions
- 27 June 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 198, 112395
Open AccessSmall numbers of clusters in cluster randomised trials: a scoping review of problems and proposed solutions
- Open Access
- 10 February 2026
- Published by Elsevier in SSRN Electronic Journal
Small numbers of clusters in cluster randomised trials: a scoping review of problems and proposed solutions
ObjectivesCluster randomised trials (CRTs) are commonly used to evaluate healthcare interventions and policies in “real-world” settings. Many CRTs include only a limited number of clusters for practical, logistical, or methodological reasons. Small numbers of clusters are associated with known analytical and design challenges, though there is little consensus on exactly what constitutes a “small” number in practice. Identifying problems and potential solutions will help researchers plan more effective evaluations.MethodsWe performed a scoping review of the literature to identify any problems and/or potential solutions related to small numbers of clusters for any type of CRT. We identified 53 references from the Ovid, MedLine and Embase databases.ResultsMost articles focus specifically either on parallel group CRTs or on stepped wedge CRTs (17 (32.1%) sources each). Challenges related to Type I error rate inflation or other inferential issues are identified in 32 (60.4%) sources, and the risk of covariate imbalance between trial arms in 30 (56.6%), making these the most commonly mentioned problems. A variety of methods to control Type I error rate inflation have been proposed, but with some concerns raised over their performance down to very small numbers of clusters. Operational definitions of a “small” number of clusters vary considerably across the literature from 3 to 50 (median 20). Most published stepped wedge trials, in particular, are what most methodological articles would call small (in terms of number of clusters).ConclusionsWork on mitigating the problems arising from small numbers of clusters has tended to focus on the analysis of CRTs rather than their design (e.g. sample size justification) or conduct. Further work is still needed to develop simple, practical guidance to help triallists understand what challenges they will face and when, and how to optimise the performance of methods for CRTs with limited numbers of clusters.
- 10 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSmall numbers of clusters in cluster randomised trials: a scoping review of problems and proposed solutions
ObjectivesCluster randomised trials (CRTs) are commonly used to evaluate healthcare interventions and policies in “real-world” settings. Many CRTs include only a limited number of clusters for practical, logistical, or methodological reasons. Small numbers of clusters are associated with known analytical and design challenges, though there is little consensus on exactly what constitutes a “small” number in practice. Identifying problems and potential solutions will help researchers plan more effective evaluations.MethodsWe performed a scoping review of the literature to identify any problems and/or potential solutions related to small numbers of clusters for any type of CRT. We identified 53 references from the Ovid, MedLine and Embase databases.ResultsMost articles focus specifically either on parallel group CRTs or on stepped wedge CRTs (17 (32.1%) sources each). Challenges related to Type I error rate inflation or other inferential issues are identified in 32 (60.4%) sources, and the risk of covariate imbalance between trial arms in 30 (56.6%), making these the most commonly mentioned problems. A variety of methods to control Type I error rate inflation have been proposed, but with some concerns raised over their performance down to very small numbers of clusters. Operational definitions of a “small” number of clusters vary considerably across the literature from 3 to 50 (median 20). Most published stepped wedge trials, in particular, are what most methodological articles would call small (in terms of number of clusters).ConclusionsWork on mitigating the problems arising from small numbers of clusters has tended to focus on the analysis of CRTs rather than their design (e.g. sample size justification) or conduct. Further work is still needed to develop simple, practical guidance to help triallists understand what challenges they will face and when, and how to optimise the performance of methods for CRTs with limited numbers of clusters.
- Open Access
Association between Dental Scores and Saliva Uremic Toxins
Dental health is frequently altered in patients with chronic kidney disease. We conducted a prospective study on dental health in CKD patients with a specific interest in the association between dental health issues and the accumulation of uremic toxins in the saliva. A total of 88 patients were included in the study, with chronic kidney disease stage 2 to 5 (without kidney replacement). We analysed the total concentrations of eight uremic toxins (trimethylamine N-oxide -TMAO-, Indoxyl Sulfate, P-cresyl-sulfate, Indole 3-acetic acid, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid -CMPF-, Kynurenine, Hippuric acid and Phenylacetylglutamine) and three precursors of uremic toxins (Tyrosine, Phenylalanine and Tryptophan) in the saliva using LC-MS/MS. We observed, for the first time, the association between various dental scores: DMFT, FST, CPITN, and OHIS, and saliva uremic toxins and precursors: TMAO, indoxyl sulfate, or hippuric acid. Further prospective interventional studies are required to confirm our results.
Open AccessAssociation between Dental Scores and Saliva Uremic Toxins
Dental health is frequently altered in patients with chronic kidney disease. We conducted a prospective study on dental health in CKD patients with a specific interest in the association between dental health issues and the accumulation of uremic toxins in the saliva. A total of 88 patients were included in the study, with chronic kidney disease stage 2 to 5 (without kidney replacement). We analysed the total concentrations of eight uremic toxins (trimethylamine N-oxide -TMAO-, Indoxyl Sulfate, P-cresyl-sulfate, Indole 3-acetic acid, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid -CMPF-, Kynurenine, Hippuric acid and Phenylacetylglutamine) and three precursors of uremic toxins (Tyrosine, Phenylalanine and Tryptophan) in the saliva using LC-MS/MS. We observed, for the first time, the association between various dental scores: DMFT, FST, CPITN, and OHIS, and saliva uremic toxins and precursors: TMAO, indoxyl sulfate, or hippuric acid. Further prospective interventional studies are required to confirm our results.